Navigation Links
Organovo to Present at the 24th Annual Oppenheimer Healthcare Conference
Date:12/2/2013

SAN DIEGO, Dec. 2, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has been invited to present at the 24th Annual Oppenheimer Healthcare Conference, which will be held in New York December 10-11, 2013.

Organovo's Chairman and Chief Executive Officer, Keith Murphy, will be presenting on Wednesday, December 11, at 2:45pm ET.

The objective of the Oppenheimer 24th Annual Healthcare Conference is to provide investors a broad spectrum of public and private healthcare companies spanning all major sectors of the healthcare industry, including bio & specialty pharmaceuticals; biotechnology; medical devices; healthcare facilities; life science tools and diagnostics; healthcare information technology and distribution, and healthcare providers and servicers.  The conference will be held at the Crowne Plaza Hotel – New York.

About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our report on Form 10-Q filed November 8, 2013, the prospectus supplement filed with the SEC on August 2, 2013 and the transition report on Form 10-KT filed with the SEC on May 24, 2013 and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

 

 

 

 


'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Organovo to Present at the 25th Annual Piper Jaffray Healthcare Conference
2. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
3. Population Council to present more than 40 studies at International Conference on Family Planning
4. Experts from NYU Langone present new research at American College of Rheumatology 2013 Annual Meeting
5. Common bias known as the endowment effect not present in hunter-gatherer societies
6. Pest control presentations at Entomology 2013
7. Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
8. Array BioPharma to Present at the NewsMakers in the Biotech Industry Conference
9. New research on potential avocado health benefits presented at International Congress of Nutrition
10. Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma
11. Yin-yang effect of sodium and chloride presents salt conundrum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com ... ... cancer conditions are being pressured as of late due to ... cancer pain management has a dramatic impact on patient,s quality ... and development activities for identifying new forms of opioid formulations ...
(Date:3/22/2017)... Freeport, Grand Bahama (PRWEB) , ... March 21, 2017 , ... ... a free educational seminar as part of their live events series, “Stem Cell Therapy: ... adult stem cell facility under the 2013 Stem Cell Research and Therapy Act, ...
(Date:3/22/2017)... Wilmington, MA (PRWEB) , ... ... ... Technology Group ( WMFTG ) has unveiled its innovative Quantum peristaltic pump ... in peristaltic innovation, Quantum sets the new standard for high-pressure feed pumps ...
(Date:3/22/2017)... 2017  Personal Genome Diagnostics Inc. (PGDx) today ... with the U.S. Department of Veterans Affairs (VA) ... the company,s new CancerSELECT ™ 125 test. ... profiling test that includes microsatellite instability status (MSI), ... to checkpoint inhibitor immunotherapies. CancerSELECT 125 will be ...
Breaking Biology Technology: